EXTENDED REPORT

IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis

Iannis E Adamopoulos,1,2,3 Erika Suzuki,2 Cheng-Chi Chao,1 Dan Gorman,1 Sarvesh Adda,1 Emanuel MaveraKis,4 Konstantinos Zarbalis,3,5 Richard Geissler,6 Agelio Asio,1 Wendy M Blumenschein,1 Terrill Mcclanahan,1 Rene De Waal Malefyt,1 M Eric Gershwin,2 Edward P Bowman1

ABSTRACT

Background Psoriatic arthritis (PsA) is a chronic inflammatory disease characterised by clinical features that include bone loss and epidermal hyperplasia. Aberrant cytokine expression has been linked to joint and skin pathology; however, it is unclear which cytokines are critical for disease initiation. Interleukin 17A (IL-17A) participates in many pathological immune responses; however, its role in PsA has not been fully elucidated.

Objective To determine the role of IL-17A in epidermal hyperplasia and bone destruction associated with psoriatic arthritis.

Design An in vivo gene transfer approach was used to investigate the role of IL-17A in animal models of inflammatory (collagen-induced arthritis) and non-inflammatory (receptor activator of NF-κB ligand (RANKL)-gene transfer) bone loss.

Results IL-17A gene transfer induced the expansion of IL-17A+CD11b+Gr1low osteoclast precursors and a concomitant elevation of biomarkers indicative of bone resorption. This occurred at a time preceding noticeable joint inflammation, suggesting that IL-17A is critical for the induction of pathological bone resorption through direct activation of osteoclast precursors. Moreover, IL-17A induced a second myeloid population CD11b+Gr1high neutrophil-like cells, which was associated with cutaneous pathology including epidermal hyperplasia, parakeratosis and Munro microabscesses formation.

Conclusions Collectively, these data support that IL-17A can play a key role in the pathogenesis of inflammation-associated arthritis and/or skin disease, as observed in PsA.

INTRODUCTION

Psoriatic arthritis (PsA) is an inflammatory rheumatic disorder of unknown aetiology occurring concurrently or before the onset of psoriasis. In PsA patients, psoriatic features of epidermal hyperplasia accompanied by parakeratosis (retention of keratinocyte nuclei in the stratum corneum) and neutrophilic exudates in the epidermis (Munro’s microabscesses) are sometimes followed many years later by synovial inflammation, bone destruction and juxta-articular new bone formation.1 Bone destruction is the result of excess differentiation and/or activation of osteoclasts, a cell uniquely specialised to carry out bone resorption.2 Osteoclast precursors circulate in peripheral blood and differentiate into multinucleated osteoclasts in the presence of macrophage-colony stimulating factor (M-CSF) and receptor activator of nuclear factor κ-B ligand (RANKL).3–5

Interleukin 17A (IL-17A), together with other T helper 17 cell (Th17)-related cytokines, has been detected in the synovium and synovial fluid of rheumatoid patients, as well as in human psoriatic skin lesions.6–7 IL-23, which plays a major role in Th17-cell development and IL-17A production, stimulates epidermal hyperplasia, entheses, synovial inflammation and bone destruction in rheumatic disease models.8–10 Although Th17 cells have been implicated in the pathogenesis of psoriasis and PsA, the contribution of IL-17A versus IL-23 or other Th17-related cytokines such as IL-22 remains puzzling.11–13 Similarly, IL-23 and IL-17A are also associated with changes in the RANKL–RANK axis and increased osteoclast formation that can lead to bone pathology.14–16 Although IL-17RA was not critical in experimental psoriasis-like skin inflammation, other reports showed that blockade of IL-17A or IL-17RA led to rapid clinical response in subjects with moderate-to-severe psoriasis.17–20 More recent evidence using IL-17A-committed γδ T cells highlighted a role of IL-17A in the development of psoriasis-like skin changes.21 Taken together, a plethora of evidence suggests a role of IL-17A in PsA pathology via indirect mechanisms involving γδ T cells, epithelial, endothelial and fibroblastic cells.

In this paper, we demonstrate a direct role of IL-17A in expanding IL-17A+CD11b+Gr1lowRANK+CSF-1R+ osteoclast precursors, which are ultimately responsible for the bone destruction observed in inflammatory arthritis. Moreover, we show that IL-17A directly expands a CD11b+Gr1high neutrophil-like cell subset associated with Munro’s microabscesses and epidermal hyperplasia with associated parakeratosis typically observed in psoriasis. Both osteoclast-mediated bone resorption and epidermal hyperplasia are hallmarks of PsA. Collectively our data support IL-17A as a possible target to combat PsA and reveal a novel link between IL-17 and cells of haematopoietic origin that are associated with joint and skin pathology observed in PsA.
METHODS
Mice and reagents
Merck Research Labs and UC Davis Institutional Animal Care and Use Committee approved all animal protocols. C57BL/6J mice (The Jackson Laboratory, Sacramento, California, USA) were sacrificed by carbon dioxide exposure and blood collected by cardiac puncture. All cell incubations were performed in culture medium consisting of α minimal essential medium (αMEM) (Invitrogen, USA), 2 mM glutamine, 10% heat-inactivated fetal bovine serum (Invitrogen), 100 IU/mL penicillin and 100 μg/mL streptomycin. Mouse M-CSF and RANKL, RANKL and IL-17A ELISA were purchased from R&D Systems (USA). Serum CTX-I and tartrate-resistant acid phosphatase 5b (TRAP5b) were measured using a RatLaps-ELIA kit from Nordic Bioscience Diagnostics A/S and ELISA from Sigma (St Louis, USA), respectively. APC-conjugated anti-mouse CD115 (AF598), PE-Cy5-conjugated anti-mouse Gr-1 (RB6-8C5), Pacific blue-conjugated anti-mouse CD11b (M1/70), biotin-conjugated anti-mouse RANKL (R12-31), Streptavidin 605 violet, Biotin and PE rat IgG2a isotypes (RTK2758), and PE-conjugated anti-mouse RANK (R12-31) were all purchased from Biolegend.

Production and purification of minicircle DNA
Mouse IL-17A and RANKL minicircle (MC)-DNA constructs were produced according to methods described previously and adjusted to 1 L culture volume. Single isolated colony from a fresh plate was grown for 8 h in 2 mL Luria–Bertani broth with ampicillin. Inoculated 800 μL of this culture onto 1 L of Terrific broth and grown for additional 17 h. Overnight cultures were centrifuged at 20°C 4000 rpm for 20 min. The pellet was resuspended 4:1 (v/v) in fresh Luria–Bertani broth containing 1% L-arabinose. The bacteria were incubated at 32°C with constant shaking at 250 rpm for 2 h. After adding one-half volume of fresh low salt Luria–Bertani broth (pH 8.0) containing 1% L-arabinose, the incubation temperature was increased to 37°C and the incubation continued for an additional 2 h. Episomal DNA circles were prepared from bacteria using the Endofree Plasmid Maxi Kit (Qiagen), and sequences were verified by sequencing on an ABI3130×1 Genetic analyser. 8 μg MC DNA were used for IL-17A and green fluorescent protein (GFP) and 0.5 μg for RANKL in all further experiments. Whole-body and liver explant images 24 h post gene transfer were obtained using a Maestro 2 (Cri).

Flow cytometry of isolated bone marrow macrophages and splenocytes
Bone marrow and spleen cells were isolated from C57BL/6J mice 3 days post gene transfer of either GFP or IL-17A MC. Splenies were treated with collagenase (Sigma) for 15 min at 37°C and then washed with FBS-containing media. Cells were dispersed into single-cell suspensions using a 70 micron nylon mesh (Fisher), washed and resuspended in 1–3 mL of ACK lysis buffer (Quality Biological, Maryland, USA) on ice for 3 min. Non-specific binding was blocked by pretreating cells with rat anti-mouse CD16/32 mAb (clone 2.4G2 BD Biosciences, San Jose, California, USA) for 10 min at room temperature. Cells were stained using predetermined optimised mAb concentration, and events (1 000 000) were collected on a FACS Aria II flow cytometer (BD Biosciences) and were analysed using FlowJo software (Tree Star, Ashland, Oregon, USA).

Mouse osteoclast cultures
Cells unlabelled or labelled with anti-RANK were sorted using FACS Aria II cell sorter (BD Biosciences). Cells were washed and cultured on 5 mm glass coverslips in a 96-well plate at 37°C with 5% CO2 for 4 days in the presence of M-CSF (25 ng/mL) and/or RANKL (60 ng/mL). The cells cultured on plastic dishes were stained for TRAP using a commercial kit (387-A, Sigma) according to manufacturer’s instructions. F-actin rings were visualised as previously described.

Collagen-induced arthritis
Female C57BL/6J mice (The Jackson Laboratory, Sacramento, California, USA) were injected with either GFP or IL-17A MC DNA 3 days before getting immunised with bovine type II collagen (CII) (Sigma-Aldrich, St Louis, Missouri, USA) emulsified in complete Freund’s adjuvant (DIFCO, Detroit, MI). 50 μL of 1 mg/mL CII/CFA emulsion was injected on both sides of the tail base. Mice were challenged intradermally 21 days later with 1 mg/mL CII emulsified in incomplete Freund’s adjuvant. Mice were observed daily and before arthritis signs were scored and processed for micro-CT imaging (μCT) as previously described.

Transmission electron microscopy
Skin samples taken from dorsal skin were fixed overnight in buffered 2.5% glutaraldehyde and 2% formaldehyde, washed in buffer, dehydrated in an ethanol series and flat embedded in epoxy resin. One-micrometer sections for light microscopy, stained with methylene blue and azure II, were reviewed with selected areas thin sectioned and then stained with uranyl acetate and lead citrate. Transmission electron microscopic imaging was performed with an FEI, Inc. model CM10 equipped with a Gatan Orius camera system.

RNA extraction and real-time quantitative PCR
Total RNA was purified from different stages of osteoclast cultures using the RNeasy Mini Kit (QIAGEN). Gene expression was calculated using the ΔΔCt method (using the mean cycle threshold value for ubiquitin and the gene of interest for each sample). The equation 1.8e (ΔCt ubiquitin–Ct gene of interest) × 10^4 was used to obtain the normalised values.

Statistical analysis
Data were analysed by Student t test and Mann–Whitney non-parametric tests as indicated in the figure legends of each assay. One-way or two-way ANOVA with Bonferroni after test were used where appropriate. p<0.05 was considered to be statistically significant (n=3, unless otherwise indicated).

RESULTS
IL-17A gene transfer in vivo induces two distinct myeloid populations
A recombinant MC construct encoding the IL-17A gene (see online supplementary figure S1) was injected hydrodynamically into the tail vein to establish systemic expression of IL-17A in vivo due to transduction of hepatocytes. A GFP MC DNA construct was also injected hydrodynamically as a negative control and could be visualised 24 h after injection using a two-dimensional (2D) fluorescence imager Maestro 2 (figure 1A,B). Stable systemic expression of IL-17A was established with 4 or 8 μg of MC DNA. Quantification of serum IL-17A taken from periodic tail bleeds demonstrated that IL-17A was stably expressed for a period of at least 24 weeks (figure 1C). Within 7 days of gene transfer, we
observed the expansion of a CD11b⁺Gr1⁺low myeloid population in the bone marrow (mean ± SD; GFP MC: 19 ± 3%; IL-17A MC: 40 ± 4%; p < 0.01) and spleen (GFP MC: 8 ± 1%; IL-17A MC: 13 ± 1%; p < 0.01). Additionally, a second myeloid population consisting of CD11b⁺Gr1⁺high cells was also expanded in the bone marrow (GFP MC: 25 ± 3%; IL-17A MC: 38 ± 4%; p < 0.01) and spleen (GFP MC: 0.6 ± 0.3%; IL-17A MC: 2.4 ± 0.6%; p < 0.01). Thus, IL-17A induces the expansion of CD11b⁺Gr1⁺low and CD11b⁺Gr1⁺high populations (figure 1D,E). These data were recorded within 7 days post gene transfer, at a timepoint when other cytokines were not detectably elevated in the serum by a multiplex bead array assay from an extensive cytokine panel.

Figure 1  IL-17A gene transfer induces myelopoiesis. (A) In vivo whole body and (B) ex vivo two-dimensional fluorescence imaging of C57BL/6 mouse liver explants 1 day post gene transfer of IL-17A or GFP. Red denotes background and green GFP. (C) Serum IL-17A levels, analysed over 24 weeks, showing stable expression after GFP or IL-17A MC transfer (p < 0.0001, Mann–Whitney non-parametric test; data pooled from three experiments). Flow cytometric analysis of (D) bone marrow cells and (E) splenocytes derived from GFP MC or IL-17A MC at day 3 depicting CD11b⁺Gr1⁺ cells (representative data of three experiments) (F) Serum cytokine levels 7 weeks post-IL-17A MC injection compared with GFP MC control mice. Data pooled from two independent experiments and 14 mice. (Dotted line shows sensitivity of each assay. p < 0.05 Mann–Whitney non-parametric test). GFP, green fluorescent protein; IL-17A, interleukin 17A; MC, minicircle.
including MIP-3α, interferon γ (IFNγ), GM-CSF, IL-4, IL-6, IL-10, IL-17E, IL-17F, IL-21, IL-23, IL-27 and tumour necrosis factor (TNF). IL-17A and IL-17E were the only two cytokines that were elevated compared with GFP controls for the first 7 days post gene transfer. Subsequent serum analysis at week 7 post gene transfer revealed a more generalised proinflammatory cytokine signature (figure 1F).

**IL-17A expands IL-17R+CD11b+Gr1−RANK+CSF-1R+osteoclast precursors and exacerbates RANKL-mediated osteoclastogenesis**

To characterise the pathologic potential of systemic IL-17A expression and the contribution of secondary cytokines downstream of IL-17A in synovial inflammation and bone destruction, we examined H&E-stained decalcified limb samples from the IL-17A MC-injected mice at 7 weeks after gene transfer. There was no evidence of visual paw swelling, nor was histological joint inflammation observed (figure 2A). Surprisingly, IL-17A MC-injected mice showed signs of systemic bone erosion by μCT in the absence of overt inflammation (figure 2B), and the increased bone resorption correlated with a significant increase in serum TRAP5b with serum RANKL remaining unchanged (figure 2C,D).

To further investigate this observation, we isolated CD11b+ cells from bone marrow and spleen of GFP MC or IL-17A MC-injected animals and characterised them by flow cytometry. Our data show that IL-17A gene transfer induced the key osteoclastogenic receptors RANK (mean±SD (1.5%±0.1%) and CSF-1R (13%±1.1%) in the bone marrow (figure 2E) and spleen (1.0%±2.0% and 2.0%±2.0%, respectively) (figure 2F).

Since both these receptors are crucial in the differentiation of monocytes to osteoclasts,24 next we sought to whether the changes in RANK expression in osteoclast precursors affected the rate of osteoclastogenesis in vivo.

Carboxy-terminal collagen cross-links (CTX-I) in serum (a marker of bone resorption) showed a non-significant increased trend in the IL-17A MC over GFP MC, which probed us to investigate the effect of IL-17A on bone destruction further (see online supplementary figure S2a,b). A RANKL expressing MC vector was injected hydrodynamically to establish systemic expression of RANKL in vivo in IL-17A or GFP overexpressing C57BL/6 mice (see online supplementary figure S2c). These experiments showed that mice with double gene transfer of IL-17A and RANKL had significantly elevated TRAP5b, which persisted 11 days (p=0.0022) and 38 days (p=0.0166) post-RANKL gene transfer (figure 2G).

**IL-17A induces osteoclast differentiation in a RANKL-dependent manner in vitro**

To validate our in vivo findings, we performed osteoclast assays in vitro by culturing bone marrow macrophages in the presence of M-CSF and RANKL. RANK+–sorted bone marrow macrophages from IL-17A MC-injected mice showed a marked increase in multinucleated TRAP+ cells that were capable of F-actin ring formation compared with GFP MC controls (figure 3A–C). This also correlated with a marked increase of IL17α, Csf1r and Nfatc1 mRNA compared with GFP MC controls (figure 3D). Finally, flow cytometric analysis revealed an increase of RANK expression on cells extracted from bone marrow after IL-17A MC injection relative to GFP MC controls (figure 3E).

**Systemic IL-17A induces cutaneous disease**

We examined H&E-stained ear and dorsal skin samples from IL-17A MC-injected mice 7 weeks post gene transfer to characterise the potential role of systemic IL-17A in skin inflammation. IL-17A gene transfer resulted in diffuse epidermal hyperplasia (acanthosis) with associated compact hyperkeratotic and parakeratosis of the stratum corneum (figure 5A). The visual skin pathology occurred randomly within a cohort of IL-17A MC-injected mice between 5 days and 8 weeks post-transfer and occurred on the ears, face, behind the neck, dorsal skin and axilla. In contrast, mice treated with control MC had a normal appearing thin epidermis and stratum corneum (figure 5B). The skin observations were in keeping with a greater than 5000-fold increase in keratin 16 (K16) mRNA, a marker of keratinocyte hyperproliferation (figure 5C). Dorsal skin excised from IL-17A MC injected mice revealed the formation of a mixed inflammatory infiltrate consisting of polymorphonuclear leukocytes (Munro’s microabscesses) in the upper dermis associated around dilated capillaries with noted uniform epidermal hyperplasia (figure 5D). The mixed inflammatory infiltrates were absent in the GFP MC controls. These cutaneous observations in the IL-17A gene transfer cohort were correlated with a dramatic (up to 80% of all nucleated blood cells) increase in neutrophils within 24 h of IL-17A gene transfer as detected by haematological analysis (figure 5E).

**DISCUSSION**

The relevance of IL-23 and IL-17 in PsA is suggested by the elevation of IL-23, IL-17/IL-17R in psoriatic skin and synovial fluid from PsA patients.8 21 Single-nucleotide polymorphisms in IL23A, IL23R, as well as TRAF3IP2 (Act1), a...
downstream target of the IL-17 receptor (IL-17R), confer susceptibility to PsA, implying a central role of the IL-23/IL-17A axis in PsA pathogenesis. Since IL-23 regulates the differentiation of IL-17-producing Th17 cells, it is hard to evaluate the significance of IL-17A in disease pathogenesis independently of IL-23 and other Th17-related cytokines. To address the direct role of IL-17A in bone and skin pathology associated with PsA, we employed a gene transfer approach to overexpress IL-17A in vivo, thereby dissecting IL-17A from the IL-23/TNF biology. IL-17A, consistent with previous reports, induced myelopoiesis and neutrophilia. Serum analysis after 1, 3, 7 days and 7 weeks showed that only IL-17A was detectable within the first 72 h; however, other cytokines were also increased with chronic exposure to IL-17A. Notably, TNF was not significantly elevated even 7 weeks post-IL-17A gene transfer. Granulocyte macrophage activating factor (GM-CSF), a cytokine known to play a role in maintaining myelopoiesis in autoimmune diseases, was...
elevated 7 weeks post gene transfer, and although it may play a role in perpetuating the myeloid signature it was not associated with the initial myelopoiesis. As there was no other cytokine apart from IL-17A directly associated with the expanded myeloid populations, our data clearly show a direct association between IL-17A and myelopoiesis in our model and confirm previous observations.

Interestingly, gene transfer of IL-17A induced serum TRAP and bone destruction as observed by μCT in the absence of synovial inflammation. This was not associated with an increase in sRANKL, but was associated with an expansion of an IL-17R⁺CD11b⁺Gr1lowRANK⁺CSF-1R⁺ myeloid population. This expanded population in the IL-17A gene transfer mice included osteoclast precursors, which showed increased differentiation capacity to osteoclasts in vivo upon RANKL gene transfer relative to GFP controls. Similarly, in vitro cultures of CD11b⁺ cells sorted from IL-17A MC also showed a higher osteoclast differentiation capacity due to increased RANK and CSF1-R expression. Collectively our data clearly show that IL-17A-induced IL-17R⁺CD11b⁺Gr1lowRANK⁺CSF-1R⁺ osteoclast precursors exacerbate bone destruction in the absence of overt inflammation.

IL-17A⁻/⁻ mice are protected from joint disease in the CIA mouse model due to reduced anti-collagen antibody titre and collagen-specific T cell proliferation; however, the role of IL-17A in initiating inflammatory arthritis remains elusive. To test this, we performed the CIA model in female C57BL/6 mice, which are resistant in this particular experimental model of arthritis in mice overexpressing IL-17A or GFP. IL-17A exacerbated the disease progression compared with GFP controls and showed a strong upregulation of Rankl, Trap and Mmp9 mRNA, correlating with the osteoclast-related gene activation signature. Based on our findings, we propose that IL-17A has at least a dual effect in inflammatory arthritis. First, IL-17A upregulates RANK on pre-osteoclasts, making them hypersensitive to RANKL signal, and second, IL-17A increases serum RANKL in the circulation. Collectively this set of data suggests a role of IL-17A in bone destruction in inflammatory arthritis.

Figure 3 IL-17A induces osteoclast differentiation in a RANKL-dependent manner in vitro. TRAP (A) cytochemical stain and (B) quantitative analysis of TRAP⁺ multinucleated (MN) cells CD11b⁺ sorted bone marrow macrophages cells from GFP or IL-17A MC-injected mice cultured for 4 days with M-CSF and RANKL. (C) F-actin ring formation assay. Data for (A) and (B) are pooled from four experiments using three mice per group. (D) qPCR of sorted RANK⁺ cells for expression of Il17ra, csf1r and Nfatc1 normalised to Gapdh (data are pooled from two experiments using three mice per group). (E) Flow cytometric analysis of RANK expression on cells extracted from bone marrow after GFP or IL-17A MC injection. Histograms are from three independent experiments. Black denotes isotype control, orange denotes GFP MC and pink denotes IL-17A MC. CSF, colony stimulating factor; GFP, green fluorescent protein; IL-17A, interleukin 17A; MC, minicircle; RANKL, receptor activator of NF-κB ligand; TRAP, tartrate-resistant acid phosphatase.
Bone and joint destruction in IL-17A gene transfer coincided with skin pathology. Specifically, a diffuse epidermal hyperplasia (acanthosis) with associated compact hyperkeratotic and parakeratosis of the stratum corneum and formation Munro’s microabscesses in the upper dermis were consistent with a greater than 5000-fold increase in keratin 16 (K16) mRNA, a marker of keratinocyte hyperproliferation. The skin pathology was absent in the GFP MC controls. These cutaneous observations in the IL-17A gene transfer cohort were correlated with a dramatic (up to 80%) increase in CD11b⁺Gr1⁺ neutrophils within 24 h of IL-17A gene transfer as detected by haematological analysis and flow cytometry. A dense accumulation of CD11b⁺Gr1⁰ neutrophils commonly occurs in Munro’s microabsscess, and their depletion reduces epidermal thickening and microabsscess formation in flaky skin mice.14–36 It is possible that IL-17A, in addition to inducing the expansion of IL-17⁺CD11b⁺Gr1⁰RANK⁺CSF-1R⁺ subset, also induces the expansion of a second myeloid cell subset, associated with the development of skin inflammation. Taken together, our data indicate that IL-17A can play a key role early on during the initiation stage of diseases involving bone and skin pathology such as psoriatic arthritis currently under investigation in proof-of-concept clinical trials.37

![Image](https://example.com/image.png)

Figure 4  IL-17A exacerbates synovial inflammation and bone loss in inflammatory arthritis. (A) Disease severity score of C57BL/6 mice post gene transfer of IL-17A or GFP, immunised and challenged with bovine collagen type II. Data pooled from two experiments and a total of 20 mice analysed. (B) Representative photographic images of inflamed mouse paws post-GFP (left) and post-IL-17A (right) gene transfer at day 37 post collagen-induced arthritis initiation showing severe inflammation in the IL-17A gene transfer. (C) H&E staining of tissue sections of paws showing infiltration of mononuclear cells, synovial lining cell hyperplasia, destruction of joint cartilage layers and fibrous ankylosis post-IL-17A gene transfer. (D) Micro-CT of mouse paws showing severe bone erosion present in IL-17A MC (right) compared with GFP controls (left). (E) Relative gene expression of RANKL, TRAP5b and MMP9 from mouse paws at 37 days post-collagen-induced arthritis initiation (data pooled from four mice). GFP, green fluorescent protein; IL-17A, interleukin 17A; MC, minicircle; RANKL, receptor activator of NF-κB ligand; TRAP, tartrate-resistant acid phosphatase.

**Figure 5** IL-17A induces skin pathology. H&E staining of cutaneous biopsies obtained from the ear 7 weeks post gene transfer of (A) GFP MC or (B) IL-17A demonstrating (asterisk) diffuse epidermal hyperplasia (acanthosis) with associated compact hyperkeratotic and parakeratosis of the stratum corneum (arrow) in IL-17A-treated mice (depicted by arrows, scale bar 100 μm). (C) Relative gene expression of K16 from C57BL/6 dorsal skin 7 weeks post gene transfer demonstrating a greater than 5000-fold increase in keratin 16 (data pooled from three experiments—Student t-test). (D) H&E staining of cutaneous biopsies obtained from dorsal skin 7 weeks post-IL-17A gene transfer showing the presence of a mixed inflammatory infiltrate in the upper dermis associated around dilated capillaries (white arrow) and uniform epidermal hyperplasia. Prominent polymorphonuclear leucocytes in the epidermis; Munro’s microabscesses (black arrow) (scale bar 200 μm). (E) Flow cytometry (ADVIA) whole blood cell count of C57BL/6 mice 7 weeks post gene transfer of both GFP and IL-17A showing a significant increase in neutrophilic infiltrate in IL-17A (right). Each dot represents individual mice, data collected from three individual experiments (p<0.0001 one-way ANOVA). Transmission electron microscopy images of dorsal skin 7 weeks post-IL-17A gene transfer showing the presence of (F) mild uniform intercellular oedema (arrow) of the epidermis with (G) retained nuclei in the upper epidermis. Scale bars for (F), (G) and (H) are 5 μm. GFP, green fluorescent protein; IL-17A, interleukin 17A; MC, minicircle.

**Table 1**

<table>
<thead>
<tr>
<th>Author affiliations</th>
<th>The authors would like to thank Drake Laface and Hong Qiu for technical assistance with hydrodynamic delivery injections.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding</td>
<td>Research was partly supported by NIH research grant R01 AR062173 and SHC 250862 to IEA. ES is the recipient of a NCATS/NIH #U1 TR000002 predoctoral fellowship.</td>
</tr>
<tr>
<td>Competing interests</td>
<td>The study was partly funded by Merck, and the authors IEA, C-CC, DG, SA, RG, AA, WMB, TM, RDWM and EPB were Merck employees at the time of the study. There are no other conflicts.</td>
</tr>
<tr>
<td>Ethics approval</td>
<td>Merck Labs and UC Davis Institutional Animal Care and Use Committees.</td>
</tr>
<tr>
<td>Provenance and peer review</td>
<td>Not commissioned; externally peer reviewed.</td>
</tr>
</tbody>
</table>

**REFERENCES**

Basic and translational research

33 Van de Velde NC, Mottram PL, Powell MS, et al. Transgenic mice expressing human FcgammaRIIa have enhanced sensitivity to induced autoimmune arthritis as well as elevated Th17 cells. *Immunology letters* 2010;130:82–8.
IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis

Iannis E Adamopoulos, Erika Suzuki, Cheng-Chi Chao, et al.

Ann Rheum Dis published online February 23, 2014
doi: 10.1136/annrheumdis-2013-204782

Updated information and services can be found at:
http://ard.bmj.com/content/early/2014/02/23/annrheumdis-2013-204782.full.html

These include:

Data Supplement
"Supplementary Data"
http://ard.bmj.com/content/suppl/2014/02/14/annrheumdis-2013-204782.DC1.html

References
This article cites 37 articles, 11 of which can be accessed free at:
http://ard.bmj.com/content/early/2014/02/23/annrheumdis-2013-204782.full.html#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Advance online articles have been peer reviewed, accepted for publication, edited and typeset, but have not not yet appeared in the paper journal. Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
Articles on similar topics can be found in the following collections

- Genetics (796 articles)
- Degenerative joint disease (3831 articles)
- Musculoskeletal syndromes (4104 articles)
- Immunology (including allergy) (4199 articles)
- Calcium and bone (619 articles)
- Inflammation (934 articles)

Notes

Advance online articles have been peer reviewed, accepted for publication, edited and typeset, but have not yet appeared in the paper journal. Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOI) and date of initial publication.

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/